Meeting slides
Suggested Readings

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19.

Dougan M, Azizad M, Chen P, et al. medRxiv. 2022. [Epub ahead of print]

Racial and ethnic health disparities related to COVID-19.

Lopez L III, Hart LH III, Katz MH. JAMA. 2021;325(8):719-720.

Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.

Hammond J, Leister-Tebbe H, Gardner A, et al. N Engl J Med. 2022;386(15):1397-1408.

Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. N Engl J Med. 2022;386(6):509-520.

Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants.

Takashita E, Yamayoshi S, Simon V, et al. N Engl J Med. 2022;387(5):468-470.

Racial and ethnic disparities in receipt of medications for treatment of COVID-19—United States, March 2020-August 2021.

Wiltz JL, Feehan AK, Molinari NM, et al. MMWR Morb Mortal Wkly Rep. 2022;71(3):96-102.

Related activities
0.50 CME/CE

Are You Up to Date on COVID-19 Diagnosis and Treatment Guidelines?

Test Your Mastery!

Faculty: Eric S. Daar, MD
Release: 08/19/2022
Expiration: 08/19/2023